Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) Operating Expenses (2023 - 2025)

Zenas BioPharma has reported Operating Expenses over the past 3 years, most recently at $238.0 million for Q4 2025.

  • Quarterly results put Operating Expenses at $238.0 million for Q4 2025, up 292.56% from a year ago — trailing twelve months through Dec 2025 was $393.1 million (up 132.73% YoY), and the annual figure for FY2025 was $393.1 million, up 132.73%.
  • Operating Expenses for Q4 2025 was $238.0 million at Zenas BioPharma, up from $52.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for ZBIO hit a ceiling of $238.0 million in Q4 2025 and a floor of $14.4 million in Q3 2023.
  • Median Operating Expenses over the past 3 years was $44.2 million (2024), compared with a mean of $60.1 million.
  • Peak annual rise in Operating Expenses hit 292.56% in 2025, while the deepest fall reached 28.29% in 2025.
  • Zenas BioPharma's Operating Expenses stood at $24.8 million in 2023, then soared by 144.65% to $60.6 million in 2024, then surged by 292.56% to $238.0 million in 2025.
  • The last three reported values for Operating Expenses were $238.0 million (Q4 2025), $52.6 million (Q3 2025), and $55.2 million (Q2 2025) per Business Quant data.